Developments since the Q2 2026 edition of the full report, published August 4, 2026. Each entry summarizes what its source states and links to the original filing, registry record or release. Entries are reviewed before they appear.
The author holds a substantial long position in ImmunityBio and is not disinterested. Entries report events without assessing them. The analysis itself is revised with each quarterly edition of the report.
Director Cheryl Cohen filed notice of a proposed sale of 81,056 ImmunityBio shares valued at about $752,000. The sale falls under a trading plan adopted February 27, 2026. Of those shares, 55,979 came from an option exercised the same day.
SEC EDGAR ↗The National Cancer Institute suspended a Phase 1/2 study of a cancer lysate vaccine, given with or without N-803, as adjuvant therapy in PD-L1-negative lung cancer. The registry gives the reason as revisions to eligibility and design before the first participant enrolled.
ClinicalTrials.gov ↗ImmunityBio withdrew a Phase 1 study of neoadjuvant nogapendekin alfa inbakicept with sotevtamab, zabadinostat, gemcitabine and nab-paclitaxel in borderline resectable or locally advanced pancreatic cancer. No patients had enrolled. The registry attributes the withdrawal to a change in development plans unrelated to safety.
ClinicalTrials.gov ↗ImmunityBio registered a Phase 2a randomized, double-blind trial comparing nogapendekin alfa inbakicept plus standard care against placebo plus standard care in critically ill adults with sepsis. The study plans to enroll about 50 patients, with 28-day all-cause mortality as its primary endpoint and a planned start of October 15, 2026.
ClinicalTrials.gov ↗ImmunityBio terminated a Phase 1 study of its CD19 t-haNK cell therapy in relapsed B-cell acute lymphoblastic leukemia after four participants enrolled. The registry states the decision was unrelated to the safety of the study drug.
ClinicalTrials.gov ↗ImmunityBio appointed Dr. Jim Yong Kim, former president of the World Bank, as Vice Chairman in a newly created Office of the Executive Chairman. He reports to Executive Chairman Patrick Soon-Shiong and focuses on the company's international and global relationships.
ImmunityBio ↗Washington University School of Medicine registered a Phase 1b study of sipuleucel-T combined with N-803 in metastatic prostate cancer resistant to androgen-pathway drugs. Dendreon and ImmunityBio are collaborators, and the study plans to enroll about 30 patients.
ClinicalTrials.gov ↗Patrick Soon-Shiong and affiliated entities reported beneficial ownership of 745,518,285 ImmunityBio shares, or 64.8% of the class, as of July 31, 2026. The filing amends the group's Schedule 13D.
SEC EDGAR ↗